Expression data from Saccharomyces cerevisiae to evaluate the impact of suppressors of Aß42 cytotoxicity on recombinant protein production

High-level production of pharmaceutical proteins in industrial microorganism is often limited due to the increased cellular stress from misfolded proteins or protein aggregates. Here, we explore the feasibility of applying a yeast Alzheimer's disease (AD) model with accumulation of amyloid-ß peptides (Aß42), which presents similar phenotypes of cellular stress. We utilize the suppressors of Aß42 cytotoxicity as potential metabolic engineering targets to improve industrial protein production. The transcriptomics analyses provide new insights towards developing synthetic yeast cell factories for biosynthesis of valuable pharmaceutical proteins. Overall design: The goal of the present study is to evaluate the impact of suppressors of Aß42 cytotoxicity on recombinant protein production in yeast. Four engineered strains (A02, A05, A08, and A16) and control strain A01 were collected from early exponential phase (OD600nm 1.0). Samples were taken from three biological replicate cultures.